Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Clinical Breast Cancer · 2024
DOI: 10.1016/j.clbc.2024.06.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Nicole Casasanta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ncasasanta19@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation, Pfizer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ncasasanta19@gmail.com.
- Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY.
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
- Frank H. Netter School of Medicine at Quinnipiac University, Department of Medicine, Hamden, CT.
- Department of Medicine, Division of Hematology and Medical Oncology, Northwell Cancer Institute, Riverhead, NY.
Förderung
- Novartis Pharmaceuticals Corporation
- Pfizer
Zitieren
APA
Casasanta, N., Patel, R., Raymond, S., Kier, M. W., Blanter, J., Sohval, S., Hovstadius, M., Wu, C., Zimmerman, B., Cascetta, K., Bagiella, E., & Tiersten, A. (2024). Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.06.005
Vancouver
Casasanta N, Patel R, Raymond S, Kier MW, Blanter J, Sohval S, et al. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.06.005
BibTeX
@article{Casasanta2024,
author = {Casasanta, Nicole and Patel, Rima and Raymond, Samantha and Kier, Melanie W and Blanter, Julia and Sohval, Sophie and Hovstadius, Malin and Wu, Catherine and Zimmerman, Brittney and Cascetta, Krystal and Bagiella, Emilia and Tiersten, Amy},
title = {Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)},
journal = {Clinical Breast Cancer},
year = {2024},
doi = {10.1016/j.clbc.2024.06.005}
}
EUVIMED